ProCE Banner Activity

Menin Inhibition in the Treatment of MLL-Rearranged Acute Leukemias: A Promising New Strategy

Clinical Thought

Learn the latest on the emerging role of menin inhibition in MLL-rearranged acute leukemias.

Released: October 26, 2022

Expiration: October 25, 2023

No longer available for credit.

Share

Faculty

Eunice S. Wang

Eunice S. Wang, MD

Chief, Leukemia Service
Medical Director, Chemotherapy/Infusion Clinic
Director, Hematologic Procurement Shared Resource
Professor of Oncology, Department of Medicine
Roswell Park Comprehensive Cancer Institute
Buffalo, New York

Provided by

ProCE Banner

Supporters

Supported by an educational grant from

Syndax

Faculty Disclosure

Primary Author

Eunice S. Wang, MD

Chief, Leukemia Service
Medical Director, Chemotherapy/Infusion Clinic
Director, Hematologic Procurement Shared Resource
Professor of Oncology, Department of Medicine
Roswell Park Comprehensive Cancer Institute
Buffalo, New York

Eunice S. Wang, MD: consultant/advisor/speaker: AbbVie/Genentech, Amgen, Astellas/Jazz, Bristol-Myers Squibb/Celgene/Kite, Daiichi Sankyo, Gilead Sciences, GlaxoSmithKline, Janssen, Kura Oncology, Mana Therapeutics, Novartis, Pfizer, PharmaEssentia, NuProbe, Rafael, Stemline, Takeda; fees for non-CME/CE services: Astellas/Jazz, Dava Oncology, Kura Oncology, Pfizer, Stemline.